Media Centre
Latest press releases
-
AstraZeneca completes equity investment agreement with Cellectis
-
Calquence combination regimen demonstrated statistically significant and clinically meaningful improvement in progression-free survival in 1st-line mantle cell lymphoma in ECHO Phase III trial
-
AstraZeneca unveils latest research across key respiratory and immune-mediated diseases at ATS 2024 showcasing strength of its broad pipeline and portfolio
-
Truqap plus Faslodex recommended for approval in the EU by CHMP for patients with advanced ER-positive breast cancer
-
Enhertu demonstrated statistically significant and clinically meaningful improvement in progression-free survival in HR-positive, HER2-low metastatic breast cancer following one or more lines of endocrine therapy in DESTINY-Breast06 Phase III trial
Medical Releases
These press releases are specifically for health specialist/medical media and are not for consumer press.
